Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
暂无分享,去创建一个
R. Carare | A. Verma | J. Dodart | J. Nicoll | L. Kelly | Jacqui Nimmo | Jacqui T. Nimmo
[1] A. Atri,et al. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering , 2021, Alzheimer's Research & Therapy.
[2] A. Kesselheim,et al. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. , 2021, JAMA.
[3] M. Mintun,et al. Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.
[4] H. Fillit,et al. Aducanumab and the FDA — where are we now? , 2021, Nature Reviews Neurology.
[5] S. Shcherbinin,et al. Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease , 2021, Alzheimer's & dementia.
[6] R. Carare,et al. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy , 2020, Alzheimer's Research & Therapy.
[7] David T. Jones,et al. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[8] D. Berry,et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.
[9] W. Poewe,et al. A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy , 2020, Movement disorders : official journal of the Movement Disorder Society.
[10] J. Cummings,et al. Alzheimer's disease drug development pipeline: 2020 , 2020, Alzheimer's & dementia.
[11] D. Boche,et al. Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials , 2020, Neuropathology and applied neurobiology.
[12] N. Penner,et al. Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain , 2020, CPT: pharmacometrics & systems pharmacology.
[13] W. Poewe,et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial , 2020, The Lancet Neurology.
[14] A. Boxer,et al. Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab , 2020, Alzheimer's & dementia.
[15] E. Masliah,et al. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo , 2019, Neurobiology of Disease.
[16] C. Holmes,et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease , 2019, Brain : a journal of neurology.
[17] R. Nitsch,et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models , 2019, Neurobiology of Disease.
[18] M. Lacaille‐Dubois. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review☆ , 2019, Phytomedicine.
[19] Eric E. Smith,et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy , 2019, Annals of clinical and translational neurology.
[20] F. Panza,et al. Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot? , 2019, Annals of neurology.
[21] L. Buée,et al. A walk through tau therapeutic strategies , 2019, Acta Neuropathologica Communications.
[22] R. Gold,et al. Emerging Immunotherapies for Parkinson Disease , 2018, Neurology and Therapy.
[23] L. Khiroug,et al. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA) , 2018, Alzheimer's Research & Therapy.
[24] J. Jankovic,et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial , 2018, JAMA neurology.
[25] S. Salloway,et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE) , 2018, Alzheimer's Research & Therapy.
[26] L. Lannfelt,et al. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody , 2018, Alzheimer's Research & Therapy.
[27] J. Cummings,et al. ABBY , 2018, Neurology.
[28] R. Doody,et al. Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005) , 2018 .
[29] J. Cedarbaum,et al. Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001) , 2018 .
[30] P. Weinreb,et al. Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration , 2018, Fluids and barriers of the CNS.
[31] L. Schneider,et al. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier coh , 2018, Alzheimer's & dementia.
[32] M. Mintun,et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.
[33] M. Andjelkovic,et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[34] M. Mintun,et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials , 2017, Alzheimer's & Dementia.
[35] Ruth Nussinov,et al. Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies , 2017, The Journal of Biological Chemistry.
[36] I. Chessell,et al. EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA-AMYLOID 42 (Aβ42)-SPECIFIC ANTIBODY, IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE , 2017, Alzheimer's & Dementia.
[37] I. Chessell,et al. PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA-AMYLOID 42 (Aβ42) , 2017, Alzheimer's & Dementia.
[38] E. Liu,et al. Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease , 2017, Current Alzheimer research.
[39] A. Börjesson-Hanson,et al. Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study , 2017, Alzheimer's & dementia.
[40] C. Jack,et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy , 2017, Alzheimer's & dementia.
[41] Pei-Ning Wang,et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease , 2017, Alzheimer's & dementia.
[42] R. P. Maguire,et al. Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study , 2016, Alzheimer's & dementia.
[43] M. Ultsch,et al. Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin , 2016, Scientific Reports.
[44] M. Grundman,et al. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.
[45] W. Suen,et al. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy , 2016, Drugs & Aging.
[46] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[47] R. Dean,et al. Quantile regression to characterize solanezumab effects in Alzheimer's disease trials , 2016, Alzheimer's & dementia.
[48] G. Logroscino,et al. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. , 2016, Immunotherapy.
[49] M. Mintun,et al. SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD) , 2016, Alzheimer's & Dementia.
[50] J. Pariente,et al. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies , 2016, Alzheimer's Research & Therapy.
[51] J. Sevigny,et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease , 2016, Alzheimer's & dementia.
[52] D. Marciani. A retrospective analysis of the Alzheimer's disease vaccine progress – The critical need for new development strategies , 2016, Journal of neurochemistry.
[53] D. Hill,et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials , 2016, Alzheimer's Research & Therapy.
[54] P. Scheltens,et al. Efficacy, Safety and Biomarker Data from SCarlet RoAD - A Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD (S1.002) , 2016 .
[55] Marc Dhenain,et al. In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy , 2016, Front. Aging Neurosci..
[56] E. Siemers,et al. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease , 2016, Alzheimer's & dementia.
[57] Robert A. Dean,et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.
[58] J. Cirrito,et al. Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity. , 2016, Brain : a journal of neurology.
[59] Donald A. Berry,et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease , 2016, Alzheimer's & dementia.
[60] T. Bayer,et al. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models , 2015, Acta Neuropathologica.
[61] J. Stavenhagen,et al. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies , 2015, Acta Neuropathologica.
[62] D. Walsh,et al. Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice , 2015, Neurobiology of Disease.
[63] E. Siemers,et al. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years , 2015, Alzheimer's & dementia.
[64] B. Dubois,et al. Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales. , 2015, The journal of prevention of Alzheimer's disease.
[65] C. Holmes,et al. Effect of amyloid‐β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)‐3β , 2015, Neuropathology and applied neurobiology.
[66] B. Winblad,et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.
[67] N. Garçon,et al. Vaccine Adjuvants: from 1920 to 2015 and Beyond , 2015, Vaccines.
[68] H. Arai,et al. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. , 2015, Current Alzheimer research.
[69] W. Schmidt,et al. Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines , 2015, PloS one.
[70] L. Ozmen,et al. Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice , 2014, The Journal of Neuroscience.
[71] E. Masliah,et al. Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models , 2014, The Journal of Neuroscience.
[72] B. Winblad,et al. Active immunotherapy options for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.
[73] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[74] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[75] Qinying Zhao,et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. , 2013, International journal of clinical pharmacology and therapeutics.
[76] P. Seubert,et al. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities , 2013, Alzheimer's & Dementia.
[77] C. Holmes,et al. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.
[78] M. Farlow,et al. Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.
[79] Lorne A. Babiuk,et al. Mechanisms of Action of Adjuvants , 2013, Front. Immunol..
[80] Qinying Zhao,et al. Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease , 2013, Clinical neuropharmacology.
[81] Qinying Zhao,et al. Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study , 2013, Clinical neuropharmacology.
[82] W. H. Jordan,et al. A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice , 2012, Neuron.
[83] P. Seubert,et al. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice , 2012, Experimental Neurology.
[84] K. Bales,et al. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. , 2012, Current Alzheimer research.
[85] J. Pons,et al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. , 2012, Journal of molecular biology.
[86] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[87] E. Siemers,et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.
[88] K. Blennow,et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.
[89] Nick C Fox,et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.
[90] F. Barkhof,et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.
[91] E. Siemers,et al. Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid &bgr; Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease , 2012, Clinical neuropharmacology.
[92] C. Holmes,et al. Microglial alterations in human Alzheimer's disease following Aβ42 immunization , 2011, Neuropathology and applied neurobiology.
[93] P. Seubert,et al. The Aβ peptide conjugate vaccine, acc-001, generates n-terminal anti- Aβ antibodies in the absence of Aβ directed t-cell responses , 2011, Alzheimer's & Dementia.
[94] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[95] M. Staufenbiel,et al. The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.
[96] E. Masliah,et al. Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.
[97] W. Schmidt,et al. AFFITOME® technology in neurodegenerative diseases: The doubling advantage , 2010, Human vaccines.
[98] E. Siemers,et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.
[99] E. Agger,et al. T‐helper 1 and T‐helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection , 2010, Immunology.
[100] Nick C Fox,et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.
[101] L. Lannfelt,et al. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.
[102] W. Schmidt,et al. Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing , 2009 .
[103] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[104] R O Weller,et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. , 2008, Brain : a journal of neurology.
[105] H. Fukuyama,et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.
[106] Sid E O'Bryant,et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.
[107] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[108] Changcai Wang,et al. Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease , 2007 .
[109] S. Paul,et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. , 2006, The Journal of clinical investigation.
[110] R. Black,et al. Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies , 2005 .
[111] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[112] L. Jenkins,et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.
[113] Kamel Jabbari,et al. Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. , 2004, Gene.
[114] I. Ferrer,et al. Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.
[115] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[116] C. Bode,et al. CpG DNA as a vaccine adjuvant , 2003, Expert review of vaccines.
[117] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[118] Walther Parson,et al. Lack of Antibody Production Following Immunization in Old Age: Association with CD8+CD28− T Cell Clonal Expansions and an Imbalance in the Production of Th1 and Th2 Cytokines1 , 2002, The Journal of Immunology.
[119] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[120] D. Holtzman,et al. Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.
[121] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[122] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[123] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[124] B. Grubeck‐Loebenstein,et al. No immunity for the elderly , 1998, Nature Medicine.
[125] D. S. Lewis,et al. Mechanisms of action , 1994, Schizophrenia Research.
[126] B. Vogelstein,et al. Molecular determinants of immunogenicity: the immunon model of immune response. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[127] C. Belden,et al. Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab. , 2016, American journal of neurodegenerative disease.
[128] Nick C Fox,et al. Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.
[129] E. Liu,et al. Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. , 2016, The journal of prevention of Alzheimer's disease.
[130] E. Liu,et al. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.
[131] E. Masliah,et al. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders , 2015, Neurotherapeutics.
[132] B. Dubois,et al. Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease. , 2015, The journal of prevention of Alzheimer's disease.
[133] G. Antoni,et al. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. , 2013, Journal of Alzheimer's disease : JAD.
[134] J. Pons,et al. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. , 2012, Journal of Alzheimer's disease : JAD.
[135] H. Loetscher,et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.
[136] Hierarchical Architectures,et al. Towards Understanding , 2011 .
[137] B. Chackerian. Virus-like particle based vaccines for Alzheimer disease. , 2010, Human vaccines.
[138] Changcai Wang,et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. , 2007, Vaccine.
[139] R. Black,et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. , 2005, Annals of neurology.
[140] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.